As we navigate through continuous change and growth at mAbxience, we are both reflective and grateful for the exceptional leaders who have shaped our journey. We mark a significant transition as Emmanuelle Lepine, our esteemed CEO, stepped down to pursue new adventures.

Over her seven-year tenure, Emmanuelle’s impact has been profound. With over two decades of experience in the pharmaceutical and biotechnology industry, she brought unparalleled expertise and vision to mAbxience. Her leadership was instrumental in transforming us into a global biopharmaceutical powerhouse, now boasting a team of over 1,000 professionals, partnerships with more than 30 global entities, and a presence in over 100 countries.

In the interim, as we seek a new leader, the mantle of leadership will be jointly held by Ayman Ibrahim, Global Head of Regulatory Affairs & Pharmacovigilance; Francisco Olivera, Global Operations Director; and Jurgen Van Broeck, Global Commercial Director. This collaborative approach ensures that mAbxience remains steadfast in its mission and vision during this transitional phase.

We extend our deepest thanks to Emmanuelle for her dedication and leadership.